Radiotherapy quality assurance in clinical trials

Area of Science:

• Radiation Oncology
• Medical Physics
• Clinical Trials

Background:

• Achieving uncomplicated local and regional tumor control is paramount in radiation therapy.
• Maintaining patient quality of life with minimal complications is an integral objective.
• Higher radiation doses and treatment volumes correlate with both tumor control and complications, necessitating optimization.

Purpose of the Study:

• To highlight the critical need for optimizing treatment planning and quality assurance in radiation therapy.
• To emphasize the importance of precise patient repositioning and immobilization for accurate radiation delivery.
• To underscore the necessity of stringent protocol adherence and dosimetry checks in clinical trials for reliable results.

Main Methods:

• Developing techniques for reliable patient repositioning and immobilization.
• Implementing stringent criteria for radiation therapy planning and delivery protocols.
• Conducting dosimetry checks through Radiological Physics Centers.
• Performing initial reviews of dosimetry factors and portal films.
• Carrying out completed case reviews to assess adherence and outcomes.

Main Results:

• Optimized treatment planning and quality assurance are crucial for balancing tumor control and complications.
• Strict adherence to protocols in multi-institutional cooperative groups is essential for reliable comparisons.
• Quality assurance programs can increase patient evaluability by 10%, decreasing cost per patient.
• A strong quality assurance program significantly enhances the reliability of clinical trial data.

Conclusions:

• Optimizing radiation therapy requires a comprehensive approach integrating treatment planning, precise delivery, and rigorous quality assurance.
• Stringent protocol adherence and dosimetry verification are vital for the success of radiation therapy clinical trials.
• Investing in quality assurance programs is cost-effective, improving data reliability and trial outcomes.